That’s why we have already exhausted all major pathways for drug mechanisms.
That’s not true there’s research like Zampaloni et al 2024 that proposes new antibiotic classes.
What did we learn? We have almost all of human history to look back at, but we don’t care.
We do care. We care so much that we essentially made the development of new antibiotics commercially unviable. Companies that managed to bring new antibiotics to market like Achaogen, Tetraphase, Nabriva Therapeutics and Melinta Therapeutics all failed commercially.
We do fund the research of people like Zampaloni but we make rules that prevent companies for selling newly developed antibiotics to people who want to buy them and therefore BioTech companies and Big Pharma has little incentive to translate research findings such as that of Zampaloni et al into a commercial products. They don’t want to suffer the same fate as Achaogen, Tetraphase, Nabriva Therapeutics and Melinta Therapeutics.
This is similar to COVID-19 an example where experts do care a lot about the problem but then make bad policy. The reason “I’m a researcher, I know about a problem, so the solution should be more research on the problem”, even if it would take something else.
I am familiar with this research, as well as how the US big pharma operates.
All that aside,
The core issue globally IS overuse.
And it IS true that we have made bacteria resistant to major pathways. Now we are exploiting new ones but the effectiveness and RoI is declining.
New drugs won’t save us. They won’t even hold the line forever. The best new drugs would be kept in reserve by doctors for the most serious resistant strains, which is why there is low commercial interest. The resistance drives this dynamic.
That’s not true there’s research like Zampaloni et al 2024 that proposes new antibiotic classes.
We do care. We care so much that we essentially made the development of new antibiotics commercially unviable. Companies that managed to bring new antibiotics to market like Achaogen, Tetraphase, Nabriva Therapeutics and Melinta Therapeutics all failed commercially.
We do fund the research of people like Zampaloni but we make rules that prevent companies for selling newly developed antibiotics to people who want to buy them and therefore BioTech companies and Big Pharma has little incentive to translate research findings such as that of Zampaloni et al into a commercial products. They don’t want to suffer the same fate as Achaogen, Tetraphase, Nabriva Therapeutics and Melinta Therapeutics.
This is similar to COVID-19 an example where experts do care a lot about the problem but then make bad policy. The reason “I’m a researcher, I know about a problem, so the solution should be more research on the problem”, even if it would take something else.
I am familiar with this research, as well as how the US big pharma operates.
All that aside,
The core issue globally IS overuse.
And it IS true that we have made bacteria resistant to major pathways. Now we are exploiting new ones but the effectiveness and RoI is declining.
New drugs won’t save us. They won’t even hold the line forever. The best new drugs would be kept in reserve by doctors for the most serious resistant strains, which is why there is low commercial interest. The resistance drives this dynamic.